Wendy Stock to Immunotherapy
This is a "connection" page, showing publications Wendy Stock has written about Immunotherapy.
Connection Strength
1.347
-
Should immunologic strategies be incorporated into frontline ALL therapy? Best Pract Res Clin Haematol. 2018 12; 31(4):367-372.
Score: 0.430
-
Progress in adult ALL: incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):28-36.
Score: 0.407
-
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Haematologica. 2012 Apr; 97(4):579-85.
Score: 0.267
-
Novel drug targets in acute leukemia. Clin Adv Hematol Oncol. 2015 Aug; 13(8):493-5.
Score: 0.086
-
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood. 2009 Aug 27; 114(9):1736-45.
Score: 0.057
-
Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia. Leuk Lymphoma. 2009 Jan; 50(1):85-91.
Score: 0.055
-
Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk Lymphoma. 2021 07; 62(7):1765-1769.
Score: 0.032
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20; 27(36):6101-8.
Score: 0.015